Compare GSK plc (GSK) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs JetBlue Airways Corporation — how do they compare? GSK plc trades at $50.39 (market cap $102.60B), while JetBlue Airways Corporation trades at $5.86 (market cap $2.19B). The key difference: GSK plc is far larger — about 46.8× JetBlue Airways Corporation's market cap, and GSK plc pays a 3.57% dividend while JetBlue Airways Corporation pays none. Which is the better fit depends on your goals.
| GSK | JBLU | |
|---|---|---|
Market Cap | $102.60B | $2.19B |
Sector | Health | Industrials |
52-Week High | $61.18 | $6.46 |
52-Week Low | $38.22 | $4.03 |
Enterprise Value | $123.04B | $9.56B |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.
GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.
JetBlue (JBLU) trades at $5.87, up 4.08% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings beat with a loss of $0.66 per share versus expectations of $0.69, though it has missed estimates in two of the last three quarters. Recent news includes Citigroup's downgrade to Sell on August 11, 2026, citing geopolitical risks, while the company introduced new fare structures and lounge accolades.
Outlook remains challenging with persistent net losses and negative margins, but cost management and strategic initiatives like the 2028 profit target offer potential upside. Key risks include high fuel costs, debt levels, and competitive pressure. Analyst consensus is cautious with a $5.18 price target and 62% Hold ratings, suggesting limited near-term growth amid operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
